The following is a summary of the Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Bio-Path Holdings reported a net loss of $3.2 million or $4.88 per share for Q1 2024, which is an improvement from a net loss of $5.3 million or $13.25 per share for Q1 2023.

• The company's cash balance as of March 31, 2024, was $0.2 million.

• Research and development expenses decreased to $2.3 million, while general and administrative expenses mildly increased to $1.4 million.

• After Q1, the company secured additional funding of $3.5 million through an at-the-market offering agreement and registered direct offering.

Business Progress:

• Bio-Path made significant advancements by receiving newly issued patents in Mexico, Australia, and Japan.

• It achieved clinical trial progress with positive interim results for acute myeloid leukemia treatment with its lead product candidate, Prexigebersen.

• The company plans to pursue FDA expedited programs for Fast Track designation for Prexigebersen AML treatment.

• Progress was noted in the BP1002 program, targeting the Bcl-2 protein and showing encouraging results in dose escalation studies.

• The Phase 1/1b clinical trial for BP1001-A for solid tumor types was launched, and progress was also made with the BP1003 program targeting the STAT3 protein.

• Processes are underway to submit an investigational new drug (IND) application to the FDA for BP1003.

More details: Bio-Path Holdings IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.